Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study.

ABSTRACT:

Background and objective

To evaluate the safety and efficacy of intravitreal sirolimus for persistent, exudative age-related macular degeneration (AMD).

Methods

This institutional review board approved, registered (NCT02357342), prospective, subject-masked, single center, randomized controlled trial in subjects with persistent, exudative Age-related macular degeneration compared intravitreal sirolimus monotherapy (every 2 months) versus monthly anti-vascular endothelial growth factor (VEGF) over six months.

Results

20 subjects were randomized to each arm of the trial. Upon completion of the trial 20 patients were analyzed in the control (anti-vascular endothelial growth factor) group and 17 patients were analyzed in the treatment (sirolimus) group. On average, subject

SUBMITTER: Minturn RJ 

PROVIDER: S-EPMC7885608 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature